We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+5.39%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
-$169M
Cap. Flow
-$38.2M
Cap. Flow %
-2.54%
Top 10 Hldgs %
63.08%
Holding
56
New
8
Increased
10
Reduced
5
Closed
4

Top Buys

1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$57.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$27M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$25.5M
4
BBIO icon
BridgeBio Pharma
BBIO
+$20.9M
5
ANTX icon
AN2 Therapeutics
ANTX
+$15.7M

Top Sells

1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$167M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$58.8M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.2M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$10.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$6.15M

Sector Composition

1 Healthcare 99.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$3.63B
$14.3M 0.95%
1,050,483
+219,500
+26% +$3.7M
TYRA icon
27
Tyra Biosciences
TYRA
$1.88B
$14.2M 0.94%
1,028,013
– –
SLNO
28
DELISTED
Soleno Therapeutics
SLNO
$13.7M 0.91%
+464,937
New +$2.81M
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.39B
$13.1M 0.87%
630,897
-226,441
-26% -$6.15M
ORIC icon
30
Oric Pharmaceuticals
ORIC
$1.11B
$13M 0.86%
2,142,855
– –
AUTL
31
Autolus Therapeutics
AUTL
$389M
$8.73M 0.58%
3,746,857
– –
SNDX icon
32
Syndax Pharmaceuticals
SNDX
$2.01B
$8.71M 0.58%
600,000
-3,108,838
-84% -$58.8M
SLN
33
Silence Therapeutics
SLN
$516M
$8.66M 0.58%
881,173
– –
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$8.58M 0.57%
393,000
– –
APGE icon
35
Apogee Therapeutics
APGE
$10.1B
$8.52M 0.57%
+400,000
New +$8.81M
MGNX icon
36
MacroGenics
MGNX
$262M
$8.4M 0.56%
1,803,204
– –
AGIO icon
37
Agios Pharmaceuticals
AGIO
$2.3B
$7.23M 0.48%
+292,002
New +$7.72M
REPL icon
38
Replimune Group
REPL
$799M
$6.62M 0.44%
386,762
– –
NTLA icon
39
Intellia Therapeutics
NTLA
$1.66B
$6.44M 0.43%
203,684
– –
PRTA icon
40
Prothena Corp
PRTA
$443M
$6.17M 0.41%
127,900
– –
THRX
41
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$6.05M 0.4%
2,248,194
– –
ARVN icon
42
Arvinas
ARVN
$518M
$5.6M 0.37%
285,331
– –
BLUE
43
DELISTED
bluebird bio
BLUE
$5.2M 0.35%
85,495
– –
EWTX icon
44
Edgewise Therapeutics
EWTX
$4.11B
$4.86M 0.32%
849,022
+100,000
+13% +$680K
DCPH
45
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.71M 0.31%
370,000
– –
STRO icon
46
Sutro Biopharma
STRO
$393M
$2.71M 0.18%
78,000
– –
GRTS
47
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.46M 0.16%
1,430,878
-970,836
-40% -$1.72M
ACRS icon
48
Aclaris Therapeutics
ACRS
$749M
$1.81M 0.12%
264,377
– –
SNDX icon
49
PUT
Syndax Pharmaceuticals
SNDX
$2.01B
$1.57M 0.1%
+600,000
New +$11.3M
ADCT icon
50
ADC Therapeutics
ADCT
$172M
$1.48M 0.1%
1,647,030
– –
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return